EDVA
Endovia Health Sciences, Inc.
There isn't enough reported data to score EDVA yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
EDVA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
EDVA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
EDVA PE Valuation
EDVA has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
EDVA Forward outlook
There aren't enough analyst estimates for EDVA to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
EDVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2024 | -$77.19 | -$1.47 |
| Q1 2024 | -$80.39 | -$0.74 |
| Q4 2023 | -$78.40 | +$12.84 |
| Q3 2021 | -$174.99 | -$154.19 |
| Q2 2021 | -$121.58 | -$107.18 |
| Q1 2021 | -$84.81 | -$70.41 |
| Q4 2020 | -$83.20 | -$76.80 |
| Q3 2020 | -$20.80 | -$19.00 |
EDVA has the stronger earnings trend. Trailing diluted EPS is down 202% for EDVA versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
EDVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $4.2K | -99% |
| Q1 2025 | $438.3K | -72% |
| Q4 2024 | $585.9K | -78% |
| Q3 2024 | $981.9K | -81% |
| Q2 2024 | $1M | -80% |
| Q1 2024 | $1.5M | -74% |
| Q4 2023 | $2.7M | -44% |
| Q3 2023 | $5.1M | +5.6% |
HIMS has the stronger quarterly revenue trend. Revenue is down 100% for EDVA versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -23176% | -22078 points |
| Q1 2025 | -464% | -253 points |
| Q4 2024 | -1098% | -976 points |
| Q3 2024 | -272% | -188 points |
| Q2 2024 | -353% | -271 points |
| Q1 2024 | -211% | -152 points |
| Q4 2023 | -122% | -23 points |
| Q3 2023 | -84% | +21 points |
EDVA's operating margin was −23176% last quarter, down 22824 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
EDVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.1M | -$411.4K |
| Q1 2026 | -$930.5K | -$206.4K |
| Q2 2025 | -$680.3K | +$1.7M |
| Q1 2025 | -$724.1K | +$583.8K |
| Q3 2024 | -$2.6M | -$663.7K |
| Q2 2024 | -$2.4M | -$9.8K |
| Q1 2024 | -$1.3M | +$2.8M |
| Q4 2023 | -$1.7M | +$1.8M |
EDVA has the stronger cash trend. Its trailing FCF is up 71% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
EDVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.6% | +27K shares |
| 1 year | +17% | +44.1K shares |
| 3 years | +80% | +136K shares |
EDVA has 306,974 diluted shares, up 17% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over EDVA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
EDVA Net Leverage
EDVA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
EDVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 7.9 | Oversold |
EDVA's weekly RSI is 31 (neutral) and its Stochastic is 8 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
EDVA PE vs Healthcare Sector
EDVA has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
EDVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.17 | 5.9% below |
| 20 week MA | $0.30 | 47% below |
| 50 week MA | $1.40 | 89% below |
| 100 week MA | $8.44 | 98% below |
| 200 week MA | $55.4 | 100% below |
EDVA is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
EDVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $524.8 | $190.4 | -64% |
| 2022 | $190.4 | $135.2 | -29% |
| 2023 | $135.2 | $88.4 | -35% |
| 2024 | $88.4 | $28.0 | -68% |
| 2025 | $28.0 | $3.85 | -86% |
| 2026 YTD | $3.85 | $0.16 | -96% |
EDVA has finished every year since 2021 lower, and it's down 96% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over EDVA on returns for 2026, with the stronger performance.